Zhengye Biotech’s Nasdaq Debut Hit by Filing Delays and Stock Downturn

Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)

Introduction

Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on livestock applications. Through its operating entity, Jilin Zhengye Biological Products Co., Ltd., the company has supplied animal health products in 29 provincial regions across China and exported vaccines to Vietnam, Pakistan, and Egypt. The ordinary shares of Zhengye began trading on the Nasdaq Capital Market under the ticker symbol ZYBT on January 7, 2025.

Veterinary vaccines by Treddy Chen

Corporate Structure

Jilin Zhengye Biological Products Co., Ltd. serves as the principal operating subsidiary. As of mid-2025, the subsidiary employs 49 professionals, each with more than ten years of experience in veterinary vaccine development. The production complex comprises three GMP-certified floors, 13 vaccine production lines, a quality examination center, and an in-house animal facility. The product portfolio includes 44 distinct vaccines—43 registered for domestic sale and six approved for export markets.

Recent Developments

• January 7, 2025: Closing of initial public offering of 1,500,000 ordinary shares at US$4.00 per share, raising US$6.0 million before underwriting discounts. Underwriters hold an option to purchase up to 225,000 additional shares. Proceeds are allocated for acquisitions of vaccine production companies and research and development projects.
• April 29, 2025: Filing of a Notification of Late Filing (Form NT 20-F) due to additional time required for the compilation and audit of the 2024 financial statements.
• May 23, 2025: Submission of Form 6-K and issuance of a press release acknowledging receipt of a Nasdaq notice regarding late Form 20-F compliance (Rule 5250(c)(1)).
• July 3, 2025: Filing of the Annual Report on Form 20-F for the fiscal year ended December 31, 2024.

Financial and Strategic Analysis

In the fiscal year 2024, Zhengye reported revenue of CNY 186.36 million, a decline of 11.95% from CNY 211.65 million in 2023. Net income decreased by 64.04% to CNY 11.31 million. As of June 30, 2024, trailing-twelve-month net profit stood at CNY 24 million against shareholders’ equity of CNY 350 million, resulting in a return on equity of 6.9%, compared with an industry average of approximately 21%. The debt-to-equity ratio was reported at 0.25. On August 21, 2025, shares traded at a price of US$6.5399, reflecting a decrease of 31.09% from the January 7 listing price, on a volume of 374,188 shares.

The use of IPO proceeds for targeted acquisitions and R&D investments aligns with management’s strategy to expand production capacity and enhance the product pipeline, as detailed in the offering prospectus and subsequent SEC filings.

Market Position and Industry Context

Zhengye operates within the veterinary vaccine segment, serving livestock species—swine, cattle, goats, sheep, and poultry—as well as companion animals such as dogs. The company’s export registrations include:

• Newcastle disease (La Sota strain) and H9 subtype avian influenza vaccines in Pakistan
• Live and inactivated Newcastle disease vaccines in Egypt and Vietnam
• Infectious bursal disease (B87 strain) in Vietnam
• A trivalent inactivated avian vaccine (La Sota, M41, and SY strains) in Vietnam

The global veterinary vaccine market is influenced by livestock health requirements, biosecurity regulations, and international trade. Zhengye’s combination of domestic coverage and selective overseas registrations positions it to serve both China’s agricultural sector and demands in emerging markets.

tl;dr

Zhengye Biotechnology closed its Nasdaq IPO on January 7, 2025, raising US$6.0 million to fund acquisitions and R&D. After notifying Nasdaq of a delayed 20-F filing (April 29 and May 23, 2025), the company filed its annual report on July 3, 2025. As of August 21, 2025, the share price stood at US$6.5399, down 31.09% from the IPO level. The immediate focus remains on integrating acquisitions, expanding vaccine production capacity, and ensuring timely financial reporting.